This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.
Why Investors Need to Take Advantage of the Zacks ESP Screener
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.
Why McKesson (MCK) Could Beat Earnings Estimates Again
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions
by Zacks Equity Research
Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience
4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market
by Zacks Equity Research
Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.
McKesson (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra's (IART) Neurosurgery Rebounds Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit
by Zacks Equity Research
According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.
Allscripts' (MDRX) Sunrise Platform Picked by Mercy Iowa City
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform gets selected by Mercy Iowa City, thereby enabling the former to help in delivering better patient outcomes and accelerating the future of healthcare.
A Very Strong Q1 and 2021 Earnings Picture
by Sheraz Mian
This improving trend in estimate revisions accelerated over the last few months, as the chart below highlighting the evolution of 2021 Q1 earnings growth estimates shows...
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Cooper Companies (COO) Now
by Zacks Equity Research
Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.
McKesson (MCK) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.